TrialESMO open2026

Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive model.

L Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.